Rafferty Asset Management LLC Sells 18,639 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Rafferty Asset Management LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 40.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,201 shares of the company's stock after selling 18,639 shares during the quarter. Rafferty Asset Management LLC owned about 0.09% of Krystal Biotech worth $4,261,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FMR LLC boosted its position in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after acquiring an additional 21,133 shares during the period. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares during the period. Avoro Capital Advisors LLC boosted its position in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after acquiring an additional 6,600 shares during the period. Hood River Capital Management LLC boosted its position in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after acquiring an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after acquiring an additional 71,200 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

KRYS stock opened at $130.60 on Monday. The company has a market capitalization of $3.77 billion, a PE ratio of 43.68 and a beta of 0.79. Krystal Biotech, Inc. has a one year low of $127.40 and a one year high of $219.34. The company's 50 day moving average price is $166.74 and its two-hundred day moving average price is $168.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

KRYS has been the subject of several research analyst reports. Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Guggenheim dropped their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup dropped their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $211.13.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.